🧩 NAC Aspergillosis Research Digest Aspergillosis (October 2025: week 43)

Highlights

  • Post‑transplant GVHD & IFI risk: In paediatric liver transplant recipients with GVHD, invasive fungal infection (aspergillosis/candidiasis) was the dominant cause of death; paper advocates PK‑guided monitoring of JAK inhibitors and tacrolimus for safer immunosuppression. (Pediatr Transplant; free full text) PMID: 41039701 | PMCID: PMC12491760
  • Inhaled opelconazole: In‑vitro + clinical data suggest negligible drug–drug interaction (DDI) risk for the investigational inhaled triazole opelconazole, supporting development for pulmonary aspergillosis. (JAC) PMID: 41105437
  • Isavuconazole DDI mapping: PBPK modelling compares isavuconazole with other azoles and proposes model‑informed dosing for anticancer drugs—useful in haem‑onc co‑prescribing. (CPT:PSP) PMID: 41104611
  • CAR‑T fungal infections: Registry analysis after CD19 CAR‑T for B‑cell lymphoma reports invasive aspergillosis as the commonest mould IFI (11/32). (CMI) PMID: 41109429
  • Air pollution & IPA: Two multicentre cohorts link higher fine particulate (PM2.5) exposure before admission with invasive pulmonary aspergillosis in severe pneumonia. (EBioMedicine) PMID: 41106023
  • Mechanisms of resistance/virulence: A bioRxiv preprint identifies a long non‑coding RNA (afu‑182) that modulates triazole susceptibility and virulence in A. fumigatus. (Preprint) PPR: PPR1101933
  • Burden estimates (Poland): National modelling updates burden for IA, CPA, ABPA, SAFS—useful for service planning and advocacy. (Sci Rep; open) PMID: 41087447 | Full text

Diagnostics

  • Dental/ENT interface: In a retrospective implant‑centred series, chronic sinusitis and aspergillosis were histopathologically confirmed in a subset of sinus augmentation candidates; authors discuss when 3D imaging is warranted pre‑procedure. (Int J Oral Maxillofac Implants) PMID: 41105467
  • Environmental surveillance: Post‑hurricane housing study identified Aspergillus spp. in water‑impacted homes, contextualising environmental exposure risk for ABPA/CPA. (Sci Rep; open) PMID: 41087584

Therapeutics & stewardship

  • Opelconazole (inhaled triazole) DDI profile appears favourable (see above). Consider future role for adjunct/targeted lung delivery once efficacy data mature. PMID: 41105437
  • Isavuconazole PBPK‑based recommendations may aid co‑administration with anticancer agents; still requires centre‑specific DDI checks and, where available, TDM. PMID: 41104611
  • Novel antifungal target: A selective acetyl‑CoA synthetase inhibitor shows antifungal activity in Nat Commun—early‑stage discovery but potentially relevant to future azole‑resistant IA/CPA. (Nat Commun; open) PMID: 41087359

Epidemiology & special populations

  • CAR‑T recipients: IA predominance among mould IFIs underscores the need for surveillance, rapid diagnostics (GM/PCR), and early therapy in post‑CAR‑T care pathways. PMID: 41109429
  • Air quality: Association between PM2.5 and IPA suggests including environmental history in risk assessments for severe pneumonia patients. PMID: 41106023
  • Veterinary reservoir: Review from Turkey highlights aspergillosis as a major poultry disease—relevance for occupational exposures and broader One‑Health messaging. (Vet Med Sci; open) PMID: 40988581

Surgery & case‑based learning

  • CPA with infected bulla: Case report supports surgical resection as an option in selected CPA phenotypes with localised disease. (Clin Case Rep; open) PMID: 41103592

Guidance / practice notes

  • For post‑transplant GVHD, ensure PK monitoring (tacrolimus, JAK inhibitors) and early IFI screening (GM/LFA ± PCR) to balance GVHD control against infection risk. PMID: 41039701
  • In CAR‑T and severe pneumonia pathways, include combined diagnostics (BAL GM, Aspergillus PCR ± culture) and rapid initiation of active triazoles where IA is probable.
  • Consider air quality and environmental exposures (post‑disaster housing, poultry) in patient education and prevention.

References & links

  • Sawada K et al. PK Monitoring of JAK Inhibitor and Tacrolimus in post‑LT GVHD. Pediatr Transplant. 2025. PMID: 41039701 | PMCID: PMC12491760
  • Cass LMR et al. Opelconazole DDIs. J Antimicrob Chemother. 2025. PMID: 41105437
  • Goosen TC et al. Isavuconazole DDI PBPK. CPT: Pharmacometrics Syst Pharmacol. 2025. PMID: 41104611
  • Bouvier A et al. IFIs after CD19 CAR‑T. Clin Microbiol Infect. 2025. PMID: 41109429
  • Zhou H et al. PM2.5 & IPA. EBioMedicine. 2025. PMID: 41106023
  • Poudyal NR et al. lncRNA afu‑182 & azole susceptibility. bioRxiv. 2025. Preprint
  • Tamagawa K et al. Lung resection in CPA with infected bulla. Clin Case Rep. 2025. PMID: 41103592
  • Vélez‑Torres LN et al. Aspergillus in water‑impacted homes. Sci Rep. 2025. PMID: 41087584
  • Krzyściak PM et al. Burden of serious mycoses in Poland. Sci Rep. 2025. PMID: 41087447
  • Alhassani ANA et al. Aspergillosis in poultry (Turkey). Vet Med Sci. 2025. PMID: 40988581

 

by GAtherton

Mannose-Binding Lectin (MBL) Deficiency and Aspergillosis

What is MBL?

Mannose-binding lectin (MBL) is a natural protein made by the immune system. Its job is to help the body recognise and fight off germs, including fungi like Aspergillus. It’s part of the “innate” immune system – the first line of defence you’re born with.

How common is MBL deficiency?

MBL deficiency is surprisingly common.

  • Around 5–10% of people have very low or absent levels.

  • If you include milder reductions, as many as 20–30% of people carry genetic changes that lower MBL activity.

For most, this causes no problems because the immune system has other pathways to fall back on. People often never know they have it.

Why do MBL levels vary?

  • Genetics: The MBL2 gene comes in different versions, some producing plenty of MBL and others producing little or none.

  • Inheritance: The combination of gene copies from each parent determines your level.

  • Normal diversity: Low levels are common and often harmless, showing the immune system has strong backup pathways.

Are some people born more vulnerable to infection?

Yes – but it depends on the situation.

  • Children with very low MBL may get more ear, chest, or sinus infections while their immune systems are developing.

  • In adults, MBL deficiency usually only matters if there are other risks, such as chronic lung disease, immune suppression, or another immune problem.

  • Many people with low MBL live their whole lives without extra infections.

MBL deficiency and aspergillosis

On its own, MBL deficiency rarely causes illness. But in people who already have other risks – such as lung disease (COPD, asthma, bronchiectasis, or TB damage) or a weakened immune system – it may make infections more likely.

Research suggests MBL deficiency can be linked to:

  • Chronic pulmonary aspergillosis (CPA)

  • Allergic bronchopulmonary aspergillosis (ABPA)

  • Invasive aspergillosis in people with suppressed immunity

In these cases, MBL deficiency is not the single cause of aspergillosis, but it may be one of several factors that increase vulnerability.

Can MBL deficiency be treated?

At present, there is no routine treatment to replace MBL itself. Research has explored giving purified MBL, but it hasn’t become a standard therapy – largely because deficiency is so common and most people remain healthy without intervention.

Instead, management focuses on:

  • Treating infections promptly with antibiotics or antifungals

  • Sometimes using preventive (prophylactic) antibiotics or antifungals in people with frequent or severe infections

  • Using immunoglobulin replacement therapy if there are additional immune problems

  • Supporting lung health and reducing risks with vaccinations, good self-care, and specialist monitoring

Why measure MBL if it can’t be treated directly?

Even without a direct treatment, measuring MBL can still be useful:

  1. Helps explain recurrent infections – finding a low MBL level can give part of the reason why someone is more prone to infections.

  2. Part of a bigger immune work-up – it’s often checked alongside other immune tests, and the overall pattern may guide treatment decisions.

  3. Risk awareness – knowing about low MBL can make doctors more proactive with antibiotics, antifungals, or vaccinations, and encourage earlier treatment at the first sign of infection.

  4. Research value – helps specialists understand why some people develop aspergillosis while others don’t.

Why hasn’t evolution eliminated low MBL?

  • Common worldwide: 5–10% of people have very little MBL, and up to 30% have reduced levels. If this were a major disadvantage, numbers would be lower.

  • Other immune pathways compensate: The body has strong backup systems, so many people stay healthy even with low MBL.

  • Possible advantage: In some infections, high MBL may drive too much inflammation. Lower MBL might have protected against diseases like leprosy or TB.

  • Changing disease patterns: In the past, people rarely lived long enough for chronic lung disease to show the effects of low MBL. Today, with longer lives and modern medicine, its role is more visible.

👉 In short: low MBL has not been “selected out” by evolution because it usually isn’t harmful on its own, and in some situations it may even have been protective.

What this means for patients

  • Having MBL deficiency is quite common and usually harmless.

  • It may become more relevant if you also have underlying lung disease or are on treatments that suppress the immune system.

  • If MBL deficiency is suspected, doctors may check for it as part of a wider immune work-up.

  • The key point: treatment is aimed at managing infections and lung health, not the MBL level itself.

👉 In short: MBL deficiency is common in the general population. Most people never notice it, but for some with lung disease or weakened immunity, it may add to the risk of aspergillosis. While there’s no direct treatment for the deficiency, testing can help explain recurrent infections, guide wider immune checks, and shape preventive care.

by GAtherton

NHS England - You and Your GP: Key Points for NHS Patients Managing Aspergillosis

You and your general practice (YYGP) has been developed to help patients understand what to expect from their general practice and how they can get the best from their GP team. YYGP also enables patient to provide feedback or raise concerns with their GP Practice, Healthwatch or the integrated care board. The contract requires every GP practice to have linked to the NHS England YYGP document on their website, no later than 1 October 2025.

1. Accessing Your GP

  • Opening hours: Your GP is typically open 8:00 – 18:30, Monday to Friday. You can walk in, call, or use the NHS App or practice website to contact them NHS England.

  • If closed: For urgent but non-emergency needs, use 111 online or by calling 111 NHS England.

  • In an emergency: If symptoms are life-threatening (e.g., sudden severe breathing issues), go to A&E or call 999 NHS England.

2. Making an Appointment

  • When you contact your GP—whether by phone, online, or in person—they’ll assess your condition and respond within one working day with next steps NHS England.

  • This could include:

    • A face-to-face appointment

    • A phone consultation

    • A text message with advice

    • A recommendation to consult a pharmacy or another NHS service NHS England.

This prompt response is especially important for aspergillosis fluctuations or side effects from antifungal treatments.

3. Who You'll See

  • You may be seen by a GP, nurse, or pharmacist.

  • If you have a designated carer, they can speak on your behalf (with your permission).

  • If you prefer a specific healthcare professional you trust, request them—though waits might be longer NHS England.

  • Seeing the same clinician regularly can be beneficial for managing complex, long-term conditions like aspergillosis NHS England.

4. Support for Additional Needs

  • If English isn't your first language, you can request interpretation services when booking an appointment.

  • If you need extra help—like longer appointments, a quiet space, wheelchair access, or materials in accessible formats—just let the practice know; they'll try to accommodate NHS England.

5. Changing or Selecting a GP

  • You can find or switch to a GP using the NHS website (“Find a GP”) or by contacting local practices directly NHS England.

  • No ID, NHS number, or proof of address is needed to register—even if you’re homeless or your immigration status is uncertain NHS England.

  • If a practice cannot register you, they must explain their decision in writing within 14 days NHS England.

6. Referral and Treatment Flexibility

  • If your GP refers you to a specialist (e.g., respiratory consultant), you often have the right to choose your hospital or clinic NHS England.

7. Free Care & Private Work

  • GP services are free, including appointments and treatments.

  • Extra services like insurance letters may incur a fee NHS England.

8. Being a Helpful Patient

  • Prepare for appointments: list symptoms, treatment concerns, and questions in advance.

  • Be punctual or cancel in good time to avoid delays for others.

  • Use the NHS App or website to book appointments, refill prescriptions, and view test results.

  • Turn on App notifications to stay updated with messages from your practice NHS England.

  • Order repeat prescriptions well ahead—especially vital when managing antifungal medications—to avoid running out NHS England.

  • Consider joining the Patient Participation Group at your practice to share feedback and help improve services NHS England.

9. Sharing Feedback or Concerns

  • To raise concerns, talk to your practice manager first.

  • If needed, you can escalate feedback to your local Integrated Care Board (ICB).

  • You can also reach out to your local Healthwatch (an independent NHS watchdog) for confidential advice and support NHS England.

Why This Matters for Aspergillosis Patients

Aspergillosis often requires ongoing monitoring, regular breathing tests, imaging, and antifungal therapy adjustments. Timely access to GP services, continuity of care, and preparedness all enhance your ability to manage flare-ups or side effects effectively.

Handy Checklist (for easy reference)

Task
Contact GP promptly for new or worsening symptoms
Prepare questions ahead—e.g., changes in breathing, treatment effects
Use NHS App to manage appointments and medications
Order repeat prescriptions early to maintain drug access
Request support services if needed (interpretation, accessibility)
Provide feedback to improve your experience and others'

by GAtherton

Damp, Cold, and Poor Housing – Why It Matters for Lung Health

This briefing from the House of Commons Library (2025) looks at how poor housing conditions—especially damp, mould, and cold homes—affect health and what’s being done about it in the UK.

Main Points

  • Health risks are serious
    Living in damp or mouldy homes increases the risk of respiratory problems, particularly for people with existing lung disease like aspergillosis, asthma, COPD, or bronchiectasis.

  • Children and vulnerable adults
    Young children, older adults, and people with weakened immune systems are most affected. Damp and mould can trigger flare-ups, worsen breathing symptoms, and increase infection risk.

  • Mental health impact
    Poor housing is linked to stress, anxiety, and depression. Worrying about your home can also worsen physical symptoms, especially if you avoid using rooms with mould or limit heating to save costs.

  • Cold homes add to the problem
    Cold airways can make breathing more difficult, weaken the immune system, and increase the chance of winter infections.

  • Wider health effects
    Damp and cold can also affect heart health, bone/joint pain, and overall wellbeing.

What’s Being Done

  • Legal responsibilities: Landlords must keep homes safe and fit to live in under UK law. This includes dealing with serious damp and mould.

  • Government programmes:

    • Funding for improving insulation and heating in social housing.

    • Advice services for tenants.

    • Local councils can take action if landlords fail to address hazards.

  • Public health guidance now recognises the link between housing and chronic illness, with stronger advice for early intervention.

What This Means for Aspergillosis Patients

  • Stay alert to symptoms: If your cough, breathlessness, or fatigue worsen at home, check for damp, mould, or poor heating.

  • Act early: Report problems to your landlord or council quickly—prolonged exposure can worsen lung damage.

  • Medical link is recognised: You are more likely to be taken seriously now, as official guidance acknowledges the health risks.

  • Keep records: Photos, symptom diaries, and GP notes can support housing complaints.

For full details see https://commonslibrary.parliament.uk/research-briefings/cdp-2025-0096/

by GAtherton

📘 What is CPA? (Chronic Pulmonary Aspergillosis)

Patient handout for A&E staff who are not aware of aspergillosis.

What is CPA?

CPA is a chronic fungal infection of the lungs caused by Aspergillus, most often in people who already have damaged lungs from conditions like tuberculosis, COPD, lung cancer, or sarcoidosis.

Unlike ABPA, CPA is a true infection, not an allergic reaction. It is not contagious but can slowly destroy lung tissue if not treated.

Symptoms

  • Chronic cough, often with mucus

  • Coughing up blood (haemoptysis)

  • Fatigue, low-grade fever

  • Unexplained weight loss

  • Breathlessness

  • Recurrent chest infections not responding to antibiotics

Diagnosis

  • CT scan of the chest showing cavities, nodules, or fungus balls (aspergillomas)

  • Aspergillus IgG antibody (usually raised)

  • Positive sputum PCR or culture for Aspergillus

  • Exclude TB and malignancy

Treatment

  • Long-term antifungal therapy (e.g. itraconazole, voriconazole, posaconazole)

  • Monitor blood levels and liver function

  • Surgery or embolisation if severe bleeding occurs

  • Supportive care: oxygen, nutrition, physiotherapy

Key Points for A&E:

✅ CPA is a progressive fungal infection, not a typical bacterial pneumonia
✅ May present with haemoptysis, respiratory distress, or systemic illness
✅ Review current antifungal treatment and potential drug interactions
✅ Consider urgent chest CT and specialist referral if patient is unwell

📍 For specialist support:

National Aspergillosis Centre (NAC)
🏥 Wythenshawe Hospital, Manchester University NHS Foundation Trust
🌐 NAC homepage on MFT website  https://mft.nhs.uk/wythenshawe/services/infectious-diseases/national-aspergillosis-centre/
🌐 www.aspergillosis.org

📞 Daytime contact: 0161 291 2891 or 0161 291 4362
📞 Urgent out-of-hours: Call Wythenshawe switchboard on 0161 998 7070
📢 Ask for the on-call Infectious Diseases Consultant

by GAtherton

📘 What is ABPA? (Allergic Bronchopulmonary Aspergillosis)

Patient handout for A&E staff who ask what aspergillosis is.

What is ABPA?

ABPA is an allergic lung condition caused by the immune system overreacting to the fungus Aspergillus. It mainly affects people with asthma or cystic fibrosis.

When Aspergillus spores are inhaled, most people clear them without issue. In ABPA, the immune system sees these spores as dangerous and mounts a strong inflammatory response. This leads to asthma-like symptoms, mucus plugging, and can result in permanent lung damage (bronchiectasis) if left untreated.

Symptoms

  • Worsening breathlessness

  • Wheezing, chest tightness

  • Coughing up thick, often brown mucus

  • Fever, fatigue, or feeling generally unwell

  • Unintentional weight loss (advanced cases)

Diagnosis

  • History of asthma or cystic fibrosis

  • High IgE levels and positive Aspergillus-specific IgE

  • Eosinophilia (raised white blood cells)

  • Sputum culture or PCR positive for Aspergillus

  • Chest imaging showing mucus plugging or bronchiectasis

Treatment

  • Oral corticosteroids (e.g. prednisolone) to reduce inflammation

  • Antifungal medication (e.g. itraconazole) to lower fungal burden

  • Biologic therapies (e.g. omalizumab or benralizumab) in some patients

  • Regular monitoring by respiratory or infectious diseases specialists

Key Points for A&E:

✅ ABPA is an allergic lung disease, not a classical infection
✅ Can present with severe asthma, mucus plugging, or type 2 respiratory failure
✅ Requires early recognition and often systemic steroids and antifungal therapy
✅ Take bloods (IgE, eosinophils, CRP), consider chest imaging, and review oxygen status

📍 For specialist support:

National Aspergillosis Centre (NAC)
🏥 Wythenshawe Hospital, Manchester University NHS Foundation Trust
🌐 NAC homepage on MFT website https://mft.nhs.uk/wythenshawe/services/infectious-diseases/national-aspergillosis-centre/
🌐 www.aspergillosis.org

📞 Daytime contact: 0161 291 2891 or 0161 291 4362
📞 Urgent out-of-hours: Call Wythenshawe switchboard on 0161 998 7070
📢 Ask for the on-call Infectious Diseases Consultant

by GAtherton

🫁 Mucus Plugging in Aspergillosis: What It Is, Why It Happens, and What It Means

For patients with ABPA, CPA, Aspergillus bronchitis, or asthma

🔍 What Is a Mucus Plug?

A mucus plug is a thick clump of sticky mucus that becomes trapped in your lungs. It can block airways, cause coughing, and make breathing more difficult. In people with aspergillosis, this is common — but the type, location, and cause of the mucus can vary.

🧪 What Causes Mucus Plugging?

Your lungs naturally make mucus to protect against germs and irritants. But in fungal or allergic lung disease, this mucus may:

  • Be produced in excess

  • Become too thick or sticky

  • Get trapped due to airway damage

Aspergillosis-related causes include:

  • ABPA (Allergic Bronchopulmonary Aspergillosis) – inflammation causes thick, sticky mucus

  • Aspergillus bronchitis – fungus lives in mucus, producing biofilms

  • CPA (Chronic Pulmonary Aspergillosis) – may lead to mucus due to structural damage

  • Bronchiectasis – airways are widened and can no longer clear mucus properly

🧬 Are All Mucus Plugs the Same?

No. Mucus plugs vary in colour, texture, cause, and treatment. Here's how they differ:

Type of Plug What You Might See What It Could Mean Common in...
Sticky, stringy Clear/yellow, like glue Allergic inflammation ABPA, asthma
Rubbery or solid Brown, rubbery, “slug-like” Allergic + fungal mix ABPA, Aspergillus bronchitis
Green or smelly Thick, foul-smelling Infection (bacteria) Bronchiectasis
Foamy or frothy Clear/white, bubbly Non-infectious irritation COPD, asthma
Black or speckled May contain fungal specks Fungal growth CPA, fungal bronchitis

🖼️ What Do Mucus Plugs Look Like on a CT Scan?

Below are real examples of CT scan findings showing mucus plugging in different forms of aspergillosis and related conditions.

🧷 1. Finger-in-glove sign (ABPA)

Mucus in large airways appears like fingers inside a glove. This is common in allergic fungal airway disease.

➡ Seen in: ABPA, bronchiectasis with fungal colonisation
📍 Note: Branching tubular opacities filled with mucus.

🌿 2. Tree-in-bud pattern

Small airway blockage — plugs in the tiniest branches of the lungs. Common in infection, inflammation, and Aspergillus bronchitis.

➡ Seen in: Aspergillus bronchitis, asthma, CPA with superinfection
📍 Note: Tiny dots and lines in a tree-like shape.

🧱 3. Lung collapse (atelectasis) from plug

A large mucus plug can block a main airway, causing collapse of part of the lung.

➡ Seen in: Severe ABPA, CPA, patients with weakened cough reflex
📍 Note: Whiteout of part of lung where plug is blocking airflow.

📸 Example CT Findings

 

1. Bronchiectasis + mucus plug
Area in the left lower lung shows dilated bronchi filled with mucus—classic for bronchiectasis with mucoid impaction

2. Extensive bronchiectasis with plugs
Widespread thick-walled airway dilatation accompanied by mucus plugs (black arrows) and consolidation (black arrowheads)

3. Luminal plugging in small airways
Subtle luminal opacities in peripheral bronchi—the “tree‑in‑bud” pattern common in asthma, COPD, and infections.

4. Atelectasis (part of the lung has collapsed or isn’t fully inflating) due to mucus plugging
Consolidation and small airway blockage leading to lung collapse, highlighted by arrows in the upper lobe.

💡 Clinical Takeaways

Feature What it indicates
Mucoid impaction Large airway fungal/allergic plugs (e.g., ABPA) or bronchiectasis
Tree‑in‑bud Small-airway infection/inflammation (e.g., TB, PCD, asthma)
Atelectasis Complete blockage, leading to collapse and consolidation
Persistent luminal plugs Associated with worse airflow obstruction and symptoms in COPD/asthma

✅ Next Steps / Applications

  • These CT examples are valuable for educational use—they illustrate the different patterns seen in mucus plugging across disease types.

  • Radiologists often use these signs to help diagnose and tailor management (infection, allergy, structural lung disease).

  • If your patients or students need simplified visuals, these scans paired with annotations (e.g., arrows, labels) can make great teaching tools.

🧠 What Does It Feel Like?

People often say:

“It felt like something was stuck and wouldn’t come out.”
“I finally coughed up a rubbery strand — like glue.”
“Once it cleared, I could breathe better instantly.”

🧼 How Are Mucus Plugs Treated?

Treatment depends on the underlying cause:

✅ Medications

  • Steroids – reduce inflammation in ABPA and asthma

  • Antifungals – lower fungal load (e.g., itraconazole, posaconazole)

  • Mucolytics – thin mucus (e.g., carbocisteine, hypertonic saline)

  • Antibiotics – treat bacterial infections

✅ Airway Clearance Techniques

  • Respiratory physio – helps you learn how to shift mucus

  • Devices – flutter valve, PEP mask, Acapella

  • Inhaled/nebulised therapy – opens airways and loosens plugs

⚠️ Always speak to your clinical team before starting a new technique.

🧪 Can Coughing Up a Plug Help Diagnosis?

Yes! If you cough up a rubbery, large, or unusual plug, it can be:

  • Tested for fungus, bacteria, or allergy cells (eosinophils)

  • Sent for culture to detect Aspergillus

  • Helpful in guiding or confirming diagnosis of ABPA or Aspergillus bronchitis

👣 Key Points for Aspergillosis Patients

Question Answer
Is mucus plugging common? Yes, especially in ABPA, CPA, and bronchiectasis
Are all mucus plugs the same? No – they vary in size, shape, colour, and cause
What should I do if I cough one up? Tell your doctor – it may be useful to test
Can it be seen on scans? Yes – CT can show where plugs are and how severe
Can it be treated? Yes – treatments include steroids, antifungals, mucolytics, and physio

by GAtherton

Patient Guide: Understanding Aspergillus-Related Chronic Pulmonary Disease

Based on new international guidance (2024)

What is Aspergillus and Why Is It Important?

Aspergillus is a common type of fungus found in the environment. Most people breathe it in every day without any problem. However, if you have a lung condition or a weakened immune system, Aspergillus can cause serious problems. It can:

  • Trigger allergic reactions in the lungs
  • Infect damaged lung tissue
  • Worsen symptoms like coughing, wheezing, or breathlessness

Until recently, doctors treated each type of aspergillus-related lung disease as a separate condition. But new guidance recognises that many patients may have more than one form or sit on a spectrum.

What Conditions Are Included?

The term "aspergillus-related chronic pulmonary disease" covers a range of conditions:

Condition What it means
ABPA (Allergic Bronchopulmonary Aspergillosis) An allergic reaction to Aspergillus, usually in asthma or cystic fibrosis patients
CPA (Chronic Pulmonary Aspergillosis) A slow-developing fungal infection, often in people with pre-existing lung damage
Aspergillus bronchitis A fungal infection in the airways, often in people with bronchiectasis
Overlap syndromes Some people show features of more than one of the above

What Are the Symptoms?

Symptoms can vary, but common signs include:

  • Persistent cough (sometimes with mucus or blood)
  • Wheezing or breathlessness
  • Fatigue and low energy
  • Weight loss or loss of appetite
  • Repeated chest infections

If you experience these symptoms and have an underlying lung condition, it’s important to ask whether Aspergillus might be involved.

How Is It Diagnosed?

Doctors now use a combination of tests to get a clearer picture:

  • Chest CT scan – to look for signs of lung damage or fungal balls
  • Sputum samples – to check for the presence of Aspergillus
  • Blood tests – to detect allergic antibodies (IgE), immune responses (IgG), or fungal antigens
  • Bronchoscopy (sometimes) – to collect samples directly from the lungs

These tests help doctors decide whether it’s an allergic reaction, an infection, or both.

How Is It Treated?

Treatment depends on your symptoms and test results. The aim is to:

  • Reduce inflammation
  • Clear fungal infection
  • Prevent further lung damage

Common treatment options include:

Treatment Purpose
Steroids (e.g. prednisolone) Reduce allergic inflammation (especially in ABPA)
Antifungal drugs (e.g. itraconazole, voriconazole) Treat fungal infection and reduce fungal burden
Biologic therapies (e.g. omalizumab, dupilumab) Used in difficult-to-treat allergic cases
Nebulised antibiotics If other infections (like Pseudomonas) are also present
Surgery (rarely) To remove fungal balls or damaged tissue in severe CPA

What Has Changed in the 2024 Guidance?

  • Doctors are now encouraged to look for overlapping features, not just one diagnosis.
  • More emphasis is placed on early detection and preventing lung decline.
  • Guidelines promote the use of multidisciplinary teams (MDTs) for complex cases.
  • Newer treatments, including biologics, are being recommended more often.
  • Patients with symptoms but unclear diagnoses should be re-evaluated regularly.

What Can You Do as a Patient?

  • Know your diagnosis – Ask your team whether your current label still fits your symptoms
  • Track your symptoms – Keep a log of cough, breathlessness, fatigue, and infections
  • Ask about specialist referral – For example, to a National Aspergillosis Centre
  • Stay informed – Visit aspergillosis.org for up-to-date guidance
  • Take medications as prescribed and report any side effects promptly

Support and Information

  • Patient support groups can help you connect with others
  • Pulmonary rehabilitation and breathing therapy can improve quality of life
  • Annual reviews and regular scans can help spot problems early

For more information, leaflets, and help getting the right care, visit: aspergillosis.org

You don’t have to manage this alone.

by GAtherton

🫁 ABPA Treatment: Why Are Steroids First, Even if They Can Increase Fungal Growth?

If you've been diagnosed with Allergic Bronchopulmonary Aspergillosis (ABPA), you may have heard that treatment often starts with oral steroids like prednisolone. But ABPA is triggered by a reaction to the Aspergillus fungus — so why use a treatment that might actually let that fungus grow more?

It’s a great question. This guide explains why steroids are still often the first step, what other treatments are available, and when they might be used.

🌿 What Is ABPA?

ABPA is not an infection — it’s an allergic immune reaction in the lungs to the fungus Aspergillus fumigatus. This overreaction causes:

  • Lung inflammation

  • Mucus plugging

  • Breathlessness and wheezing

  • Possible long-term lung damage (e.g., bronchiectasis)

People with asthma or cystic fibrosis are more likely to develop ABPA.

💊 Why Are Steroids Usually the First Treatment?

🔥 The key problem in ABPA is inflammation, not the fungus itself.

Steroids like prednisolone are often used first because they:

  • Act quickly to calm the allergic immune reaction

  • Reduce inflammation and mucus

  • Help relieve symptoms fast (wheezing, tight chest, breathlessness)

  • Prevent long-term damage if started early

Even though steroids may allow some fungal growth, their fast action against inflammation is often more important — especially in flare-ups.

🍄 What About Antifungal Treatments?

Antifungals like itraconazole or posaconazole reduce the amount of Aspergillus in the lungs. This helps to:

  • Reduce allergic triggers

  • Prevent future flare-ups

  • Lower the need for steroids

However, antifungals:

  • Take weeks to work

  • Don’t control inflammation well on their own during a flare

  • Can have side effects and interact with other medications

➡️ That’s why they are often used after steroids, or alongside them — especially in people who flare up often or need steroids long term.

🧬 What About Biologics?

Biologic therapies like:

  • Omalizumab (anti-IgE)

  • Dupilumab (blocks IL-4 and IL-13)

  • Mepolizumab (anti-IL-5)

…are used to help regulate the immune system in patients who:

  • Can’t tolerate steroids

  • Have frequent relapses

  • Need ongoing treatment despite antifungals

Biologics can help:

  • Reduce steroid use

  • Lower flare frequency

  • Improve asthma control

But they’re not yet approved as first-line treatments and are generally reserved for more complex or persistent cases.

✅ What Happens If My Symptoms Are Mild?

Good question. In mild ABPA (e.g. stable breathing, low IgE, no major lung damage), specialists may:

  • Monitor closely before starting any treatment

  • Try antifungals alone, especially if steroid use is risky

However, regular follow-up is essential to make sure inflammation doesn’t silently worsen.

🔄 Typical ABPA Treatment Steps

Stage Treatment
First flare or moderate symptoms Steroids (short course) ± antifungals
Steroid side effects or long-term use Add antifungals
Recurrent or steroid-dependent ABPA Add or switch to biologics
Mild symptoms and stable lungs Possibly antifungals first (specialist decision)

🧘 Staying Well with ABPA

  • Follow your treatment plan closely

  • Keep lungs clear with mucus clearance techniques

  • Avoid damp, mouldy environments

  • Keep up with regular check-ups and lung tests

  • Let your team know if symptoms return

🗨️ In Summary

Steroids are still first-line because they work fast to stop inflammation.
Antifungals and biologics are important longer-term options that help reduce fungal triggers and flare-ups — and may reduce or even replace steroids over time.

Every ABPA patient is different, and your care should be tailored to you.

by GAtherton

🫁 Understanding ABPA, Bronchiectasis & Lung Cavities

A Patient’s Guide to What Happens in the Lungs – and What You Can Do About It

🌿 What is ABPA?

Allergic Bronchopulmonary Aspergillosis (ABPA) is a condition where the lungs react strongly to a common fungus called Aspergillus. This overreaction causes inflammation in the airways, making it harder to clear mucus and increasing the risk of flare-ups.

Many people with asthma or cystic fibrosis are more likely to develop ABPA, but it can affect others too.

🌀 What Happens to the Lungs?

Over time, repeated inflammation and mucus build-up can affect the structure of the airways. Here’s what can happen:

1. Bronchiectasis

  • The airways (bronchi) become widened and thickened.

  • This makes it harder to clear mucus, which can lead to more infections.

  • In ABPA, this usually affects the central parts of the lungs.

🔸 Bronchiectasis is not the same as a lung cavity. It’s a change in the shape of the airways, not a hole in the lung.

2. Lung Cavities (Less Common)

  • These are air-filled spaces that form when a small area of lung tissue is damaged or infected.

  • Cavities are less common in ABPA but can happen after repeated inflammation or infection.

  • They may look worrying on a scan, but often they are just monitored and don’t cause major issues unless they become infected.

🩺 What About Lung Function?

ABPA and bronchiectasis can affect lung function, especially if not caught early.

  • Spirometry tests may show lower results if the airways are blocked or inflamed.

  • Some people improve after treatment; others may see a gradual decline.

  • Most patients still breathe well at rest, and many stay active with proper care.

🌬️ Will Cavities Leak Air?

This is a common worry. The answer is: usually not.

  • Most cavities in ABPA are not at risk of bursting or leaking.

  • Sudden breathlessness or chest pain should always be checked, but leaks (pneumothorax) are rare in ABPA.

📉 Does Everyone Get Cavities?

Not at all.

  • Around 50–90% of ABPA patients get some bronchiectasis.

  • Only a minority go on to develop true cavities.

  • Early treatment and regular check-ups help reduce the risk of further lung changes.

🧪 What About Oxygen Levels?

Many people with ABPA — even with bronchiectasis — still have normal oxygen levels (SpO₂):

  • Most rest between 95–98%

  • During a flare or infection, it might dip a little

  • If oxygen drops below 92%, your team may check more closely

🧘 What Can I Do to Stay Well?

  • 🩺 Stick to your treatment plan – antifungals, inhalers, or steroids if prescribed

  • 💨 Clear mucus regularly – ask about airway clearance techniques

  • 🧼 Avoid damp, mouldy environments

  • 🍎 Stay active and eat well

  • 📆 Attend check-ups and lung function tests

  • 🚭 Avoid smoking or vaping (these can worsen damage)

💬 A Final Word

Having ABPA and some lung changes doesn’t mean life has to stop. Many people continue to live active, fulfilling lives. Even with bronchiectasis or small cavities, the focus is on prevention, staying stable, and getting support when needed.

by GAtherton